Clinical trials: Pneumococcal Disease, Invasive
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal, Streptococcus Pneumoniae
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S.
- Trial name
- FinIP (NCT00861380)
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- Finland
- Volunteers
- 41,188 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)
The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infancy is to demonstrate that the…
- Trial name
- NCT00617760
- Testing
- Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
- Where
- 27 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in…
- Conditions
- Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM), Invasive Pneumococcal Disease, Protection Against
- Trial name
- Nunavik2 (NCT01694329)
- Where
- Canada
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Infections, Streptococcal
Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoniae
GSK Biologicals is working on the development of a vaccine to protect elderly people from pneumococcal infection. For the future studies in that project, it would be useful to have some easy non invasive tests to detect infection…
- Trial name
- NCT00523770
- Testing
- Urine sample collection
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease, Invasive
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
- Trial name
- NCT06790290
- Testing
- Formulation B, Formulation C, Formulation D
- Where
- 3 sites in Philippines
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Streptococcal Pneumonia
A Study of Streptococcus Pneumonia Colonisation and Invasive Disease in Cambodian Children
Streptococcus pneumoniae (the pneumococcus) remains a leading cause of childhood mortality and morbidity. Between 2007 and 2012, Angkor Hospital for Children (AHC), Siem Reap, Cambodia documented that S.
- Trial name
- PCV (NCT03331952)
- Testing
- Prospective study, Cross-sectional surveys
- Where
- Cambodia
- Volunteers
- 4,111 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.
- Trial name
- NCT02034877
- Testing
- 13-valent Pneumococcal conjugate vaccine, Blood sample collection
- Where
- 16 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Streptococcus Pneumoniae Disease
An Alternative Booster Vaccine Against Meningitis and Ear Infections
This is a study to evaluate an alternative booster for pneumococcal conjugate vaccination (PCV) for children at 12 months of age.
- Trial name
- NCT01443416
- Testing
- 13-valent pneumococcal conjugate vaccine, 10-valent pneumococcal conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pneumococcal Infections
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
This study will evaluate whether the aluminum-adjuvanted or the non-adjuvanted formulation of the candidate pneumococcal vaccine (V114) is non-inferior to Prevnar 13® based on immune responses to the 13 serotypes in common…
- Trial name
- NCT01215188
- Testing
- V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13®
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal
Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
To explore a further dimension of susceptibility to disease, the investigators tested the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that…
- Trial name
- NCT03460730
- Testing
- Pneumovax
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Pneumococcal Disease, Invasive, Pneumococcal Disease
Serum Collection Study for Assay Development
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
- Trial name
- NCT07205289
- Testing
- Gamma-PN
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infection, Streptococcus Pneumoniae Infection
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis…
- Conditions
- Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
- Trial name
- FPCV (NCT03489018)
- Testing
- PCV10, PCV13
- Where
- Kenya
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3…
- Trial name
- NCT03384589
- Testing
- PCV13
- Where
- Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Pneumococcal Nasopharyngeal Colonization, Invasive Pneumococcal Disease
Impact of PCV on Disease and Colonization Among Native American Communities
The purpose of this study is to determine the impact of pneumococcal conjugate vaccine on carriage of pneumococcus in the nasopharynx and on the incidence of invasive pneumococcal disease in the community.
- Trial name
- NCT01083459
- Where
- 2 sites in United States
- Volunteers
- 6,628 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population
As the licensed pneumococcal vaccine is not always satisfactory in elderly, new investigational pneumococcal vaccines are evaluated in the healthy elderly population.
- Trial name
- NCT00327665
- Testing
- 11-valent pneumococcal vaccine GSK513026, Pneumo 23™, 10-valent pneumococcal vaccine GSK513026
- Where
- 3 sites in Belgium, Finland and 1 more
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline